PHG vs MDT Stock Comparison: AI Score, Valuation, Performance and Upside
Philips and Medtronic both operate in medical devices and diagnostic technology, but Philips concentrates more on diagnostic imaging and connected care solutions while working through prior quality remediation challenges, while Medtronic operates a much larger, more diversified portfolio spanning cardiac, neuroscience, surgical, and diabetes device categories.
Philips offers recovery potential tied to diagnostic imaging demand and remediation progress, while Medtronic offers exposure to a larger, more diversified global medical device portfolio. Consider whether you prefer Philips's recovery turnaround story or Medtronic's diversified device scale.
MDT holds the edge across 5 of 5 key metrics in this comparison. MDT leads on both 1-year return (+16.08%) and forward P/E quality (14.24x vs 16.46x for PHG), a relatively favorable combination of momentum and valuation. MDT leads on both revenue growth (9.90%) and operating margin (22.05%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for MDT (+8.34%) than for PHG (+3.09%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- See recovery upside potential as quality and regulatory remediation progress continues
- Believe diagnostic imaging equipment demand will benefit from hospital capital equipment replacement cycles
- Value the broad health technology portfolio spanning imaging, monitoring, and connected care
- Are comfortable with the execution risk inherent in an ongoing turnaround story
- Want exposure to a highly diversified global medical device portfolio spanning cardiac, neuroscience, surgical, and diabetes categories
- Value the scale and research and development resources of one of the largest medical device companies
- Believe established hospital relationships worldwide support consistent long-term product demand
- Prefer a larger, more diversified device business over a more concentrated turnaround story
| Metric | PHG | MDT |
|---|---|---|
| AI scorei | 39.8 | 42.6 |
| AI ranki | #2325 | #1218 |
| Latest closei | $31.06 | $104.96 |
| 1M returni | +29.90% | +19.31% |
| 3M returni | +16.81% | +22.06% |
| 6M returni | +18.51% | +35.26% |
| 1Y returni | +15.17% | +16.08% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PHG | MDT |
|---|---|---|
| 1Y ago | $11.97K (+19.7%) started 2025-11-04 | $11.61K (+16.1%) started 2025-11-05 |
| 5Y ago | $8.28K (-17.2%) started 2021-11-05 | $10.73K (+7.3%) started 2021-11-08 |
| 10Y ago | $15.86K (+58.6%) started 2016-11-07 | $19.72K (+97.2%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | PHG | MDT |
|---|---|---|
| Market capi | $30.36B | $116.77B |
| Trailing P/Ei | 64.71 | 24.46 |
| Forward P/Ei | 16.46 | 14.24 |
| Price/Salesi | 1.71 | N/A |
| EV/Revenuei | 2.02 | 3.78 |
| Analyst targeti | $32.02 | $98.84 |
| Target upsidei | +3.09% | +8.34% |
| Metric | PHG | MDT |
|---|---|---|
| Revenue growthi | 2.10% | 9.90% |
| Earnings growthi | -85.40% | 18.30% |
| EPS growthi | -85.40% | +18.30% |
| FCF margini | +10.34% | +12.72% |
| Operating margini | 3.76% | 22.05% |
| Profit margini | 5.39% | 13.20% |
| ROIC proxyi | 8.61% | 9.84% |
| Return on equityi | 8.61% | 9.84% |
| Dividend yieldi | 3.26% | 3.16% |
| Payout ratioi | 211.79% | 70.02% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 1.21 | 0.57 |
| Debt/equityi | 70.11 | 58.21 |
| Current ratioi | 1.33 | 2.13 |
| Quick ratioi | 0.81 | 1.36 |
Over the past year, PHG and MDT have moved moderately in the same direction (correlation of 0.40), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PHG | MDT |
|---|---|---|---|
| 1Y | Growthi | +15.17% | +16.11% |
| CAGRi | +15.18% | +16.13% | |
| Volatilityi | 29.35% | 26.19% | |
| Sharpe ratioi | 0.47 | 0.54 | |
| Sortino ratioi | 0.75 | 0.87 | |
| Max drawdowni | 24.83% | 30.00% | |
| Current drawdowni | 1.94% | 0.37% | |
| Avg drawdowni | 12.85% | 13.91% | |
| Ulcer Indexi | 14.47% | 16.09% | |
| Max daily dropi | 5.68% | 5.11% | |
| Max wkly dropi | 9.59% | 7.05% | |
| 5Y | Growthi | -26.75% | -4.62% |
| CAGRi | -6.04% | -0.94% | |
| Volatilityi | 37.83% | 22.88% | |
| Sharpe ratioi | -0.10 | -0.12 | |
| Sortino ratioi | -0.14 | -0.17 | |
| Max drawdowni | 74.59% | 39.97% | |
| Current drawdowni | 27.41% | 4.62% | |
| Avg drawdowni | 46.01% | 22.60% | |
| Ulcer Indexi | 47.51% | 23.84% | |
| Max daily dropi | 15.95% | 7.26% | |
| Max wkly dropi | 18.61% | 11.81% | |
| 10Y | Growthi | +26.43% | +55.15% |
| CAGRi | +2.38% | +4.49% | |
| Volatilityi | 32.06% | 23.81% | |
| Sharpe ratioi | 0.09 | 0.12 | |
| Sortino ratioi | 0.13 | 0.16 | |
| Max drawdowni | 79.61% | 45.10% | |
| Current drawdowni | 41.76% | 12.77% | |
| Avg drawdowni | 32.29% | 17.90% | |
| Ulcer Indexi | 41.36% | 22.19% | |
| Max daily dropi | 15.95% | 12.82% | |
| Max wkly dropi | 19.10% | 19.36% |
| Category | PHG | MDT |
|---|---|---|
| Company | Koninklijke Philips N.V. | Medtronic plc |
| Sector | Medical Devices | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A health technology company providing diagnostic imaging equipment, patient monitoring systems, and connected care solutions to hospitals and healthcare providers, alongside a personal health products business. | A diversified global medical device company providing products across cardiac, neuroscience, medical surgical, and diabetes categories, serving hospitals and healthcare providers with a broad range of therapeutic technologies. |
| Investor focus | Diagnostic imaging equipment order trends, quality and regulatory remediation progress, and margin recovery following prior product-related challenges. | Cardiac and diabetes segment growth trends, new product launch execution, and overall revenue growth trajectory across diversified device categories. |
- Established position in diagnostic imaging equipment provides recurring demand from hospital capital equipment replacement cycles
- Broad health technology portfolio spans imaging, patient monitoring, and connected care solutions
- Global brand recognition and distribution network support access to healthcare provider customers worldwide
- Highly diversified product portfolio spans cardiac, neuroscience, surgical, and diabetes categories, reducing reliance on any single device category
- Massive scale as one of the largest medical device companies provides broad distribution and research and development resources
- Established relationships with hospitals and healthcare systems worldwide support consistent product demand
- Prior product quality and regulatory remediation issues have created financial and reputational overhang requiring ongoing resolution
- Diagnostic imaging equipment demand is sensitive to hospital capital spending cycles and budget conditions
- Recovery in margins and growth requires sustained execution on remediation and operational improvement initiatives
- Diversified portfolio scale can make it harder to sustain above-market growth rates across all segments simultaneously
- Competitive dynamics in cardiac and diabetes device categories include well-resourced specialized competitors
- Regulatory and product quality compliance across such a broad portfolio requires extensive ongoing investment
Compare more than two at a time
This page is a fixed writeup on PHG and MDT. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside PHG and MDT, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.